Forge And Basilea Enter Into Multi-Target Agreement To Discover And Develop Novel Antibiotics

  27 April 2019

Forge Therapeutics, Inc. (Forge) and Basilea Pharmaceutica International Ltd. (Basilea), a wholly-owned subsidiary of Basilea Pharmaceutica Ltd. [SIX: BSLN], announced that they have entered into a research collaboration and license agreement to discover, develop, and commercialize novel antibiotic classes. They will apply Forge’s proprietary BLACKSMITH metalloenzyme chemistry platform to develop potent and selective inhibitors against two historically difficult-to-drug, unexploited antibiotic targets.

Further reading: Forge Therapeutics
Smart Innovations  
Back

OUR UNDERWRITERS

Unrestricted financial support by:

Antimicrobial Resistance Fighter Coalition

Evotec

JSS University

INTERNATIONAL FEDERATION PHARMACEUTICAL MANUFACTURERS & ASSOCIATIONS





Technology Database

Display your AMR Technology, Product and Service

Suppliers and Users of Technologies, Products and Services benefit from CAPI.
CAPI (Continuous AMR Partnering Initiative) unites Suppliers and Users worldwide with the aim to add to the curbing of AMR.

Read more and make your own Technology Page >>
What is going on with AMR?
Stay tuned with remarkable global AMR news and developments!